top of page
Ending
Brain
Disease
Starts
Here.
The TRanslational Initiative to DE-risk NeuroTherapeutics
(TRIDENT) is revolutionizing preclinical trials for the treatments
of neurodegenerative diseases with a $24 million grant from the Government of Canada's New Frontiers In Research program
“We are creating a
one-stop shop to identify and predict the success of drugs
in human trials faster and cheaper.”
- Dr. Ravi Menon,
Principal Investigator for TRIDENT
bottom of page